Prasterone sulfate
Clinical data | |
---|---|
Trade names | Astenile, Levospa, Mylis, Teloin |
Routes of administration | Injection[1] |
Identifiers | |
| |
Synonyms | DHEA sulfate; DHEA-S; Sodium prasterone sulfate; Sodium prasterone sulfate hydrate; KYH-3102; NSC-72822; PB-005[2][3] |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H28O5S |
Molar mass | 368.488 g/mol |
3D model (JSmol) | |
| |
|
This article is about DHEA sulfate as a medication. For as a natural hormone, see DHEA sulfate.
Prasterone sulfate (brand names Astenile, Levospa, Mylis, Teloin), also known as dehydroepiandrosterone sulfate (DHEA-S), is a naturally occurring androstane steroid which is marketed and used in Japan as a labor inducer in the treatment of insufficient cervical ripening and dilation during childbirth.[4][5][6][2][7][1][8][9] It is the C3β sulfate ester of prasterone (dehydroepiandrosterone; DHEA), and is known to act as a prohormone of DHEA and by extension of androgens and estrogens,[10] although it also has its own activity as a neurosteroid.[11] Prasterone sulfate is used medically as the sodium salt via injection and is referred to by the name sodium prasterone sulfate (JAN).[9][12]
See also
References
- 1 2 Sakaguchi M, Sakai T, Adachi Y, Kawashima T, Awata N (1992). "The biological fate of sodium prasterone sulfate after vaginal administration. I. Absorption and excretion in rats". J. Pharmacobio-dyn. 15 (2): 67–73. PMID 1403604.
- 1 2 Martin Negwer; Hans-Georg Scharnow (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 1831. ISBN 978-3-527-30247-5.
3β-Hydroxyandrost-5-en-17-one hydrogen sulfate = (3β)-3-(Sulfooxy)androst-5-en-17-one. R: Sodium salt (1099-87-2). S: Astenile, Dehydroepiandrosterone sulfate sodium, DHA-S, DHEAS, KYH 3102, Mylis, PB 005, Prasterone sodium sulfate, Teloin
- ↑ Cynthia A. Challener (1 December 2001). Chiral Drugs. Wiley. ISBN 978-0-566-08411-9.
[...] Mylis; NSC 72822; Prasterone sodium sulfate; Prasterone sodium sulfate; Sodium dehydroepiandrosterone sulfate; [...]
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
- ↑ John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
- ↑ Kleemann A, Engel J, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 2441–2442. ISBN 978-3-13-179525-0.
- ↑ Jianqiu, Y. (1992). Clinical Application of Prasterone Sodium Sulfate. Chinese Journal of New Drugs, 5, 015.
- ↑ Sakai, T., Sakaguchi, M., Adachi, Y., Kawashima, T., & Awata, N. (1992). The Biological Fate of Sodium Prasterone Sulfate after Vaginal Administration II: Distribution after Single and Multiple Administration to Pregnant Rats. 薬物動態, 7(1), 87-101.
- 1 2 https://www.drugs.com/international/prasterone.html
- ↑ Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA (2015). "The Regulation of Steroid Action by Sulfation and Desulfation". Endocr. Rev. 36 (5): 526–63. PMC 4591525 . PMID 26213785. doi:10.1210/er.2015-1036.
- ↑ Gibbs TT, Russek SJ, Farb DH (2006). "Sulfated steroids as endogenous neuromodulators". Pharmacol. Biochem. Behav. 84 (4): 555–67. PMID 17023038. doi:10.1016/j.pbb.2006.07.031.
- ↑ https://chem.nlm.nih.gov/chemidplus/rn/1099-87-2
Cervical ripening | |||||
---|---|---|---|---|---|
Contraction induction | |||||
|
AR |
| ||||||
---|---|---|---|---|---|---|---|
GPRC6A |
| ||||||
|
ER |
| ||||||
---|---|---|---|---|---|---|---|
GPER |
| ||||||
|
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
| ||||||||||||||||||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
Receptor (ligands) |
| ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
| ||||||||||||||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||
See also: Receptor/signaling modulators • GABAergics • GHBergics • Glycinergics |
Angiopoietin |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF | |||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
| ||||||||||
|
AhR |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CAR |
| ||||||||||||||||||||||||||||||
ERR |
| ||||||||||||||||||||||||||||||
FXR |
| ||||||||||||||||||||||||||||||
LXR |
| ||||||||||||||||||||||||||||||
PPAR |
| ||||||||||||||||||||||||||||||
PXR |
| ||||||||||||||||||||||||||||||
RAR |
| ||||||||||||||||||||||||||||||
RXR |
| ||||||||||||||||||||||||||||||
SHR |
| ||||||||||||||||||||||||||||||
THR |
| ||||||||||||||||||||||||||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.